How much revenue does Zhuhai Rundu Pharmaceutical make?

Zhuhai Rundu Pharmaceutical reported 1.18 billion CNY in revenue for fiscal year 2025, down 0.5% from 1.18 billion CNY in fiscal year 2024. In Q1 2026 revenue was 348.71 million CNY.

What is Zhuhai Rundu Pharmaceutical's largest business segment?

Chemical Pharmaceutical Manufacturing, with 683.29 million CNY or 58% of segment revenue in fiscal year 2024. Next: Manufacturing of Active Pharmaceutical Ingredients (42%).

Where does Zhuhai Rundu Pharmaceutical make most of its revenue?

East China: 31% of revenue by region in fiscal year 2024, followed by South China (20%).

What companies are similar to Zhuhai Rundu Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ), Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ), Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ), Beijing Centergate Technologies (holding) Co., Ltd. (000931.SZ).

Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ) Stock

About Zhuhai Rundu Pharmaceutical Co., Ltd.

Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes d...

At a glance

Zhuhai Rundu Pharmaceutical reported revenue of 1.18 billion CNY for fiscal year 2025, down 0.5% from fiscal year 2024, and net income of -63.47 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 348.71 million CNY, up 36.9% from a year before. Its largest business segment, Chemical Pharmaceutical Manufacturing, brought in 58% of segment revenue in fiscal year 2024; East China was the largest region with 31%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.